DR. STEVEN PORCELLI
Osteopathic Medicine at Pelham Pkwy, Bronx, NY
License number
New York 223183
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
1400 Pelham Pkwy S, Bronx, NY 10461
Phone
(718) 918-3060
(718) 918-4469 (Fax)
(718) 918-4469 (Fax)
Personal information
See more information about STEVEN PORCELLI at radaris.comName
Address
Phone
132 Horton St APT 1B, Bronx, NY 10464
333 W Hartsdale Ave, Hartsdale, NY 10530
377 Vineyard Ave, Highland, NY 12528
Bronx, NY
86 Reynolds St, Bronx, NY 10464
Organization information
See more information about STEVEN PORCELLI at bizstanding.comSteven A Porcelli
1300 Morris Park Ave, Bronx, NY 10461
Industry:
Grant Reviewer
Steven Porcelli MD
1300 Morris Park Ave, Bronx, NY 10461
Industry:
Internist
Phone:
(718) 430-3228 (Phone)
Steven Anthony Porcelli
Professional information
Dr. Steven Porcelli, Bronx NY - MD (Doctor of Medicine)
Specialties:
Rheumatology
Address:
1400 Pelham Pkwy S, Bronx 10461
(718) 918-3060 (Phone), (718) 918-4469 (Fax)
JACOBI MEDICAL CENTER
1400 Pelham Pkwy S, Bronx 10461
(718) 918-5000 (Phone), (718) 918-6318 (Fax)
(718) 918-3060 (Phone), (718) 918-4469 (Fax)
JACOBI MEDICAL CENTER
1400 Pelham Pkwy S, Bronx 10461
(718) 918-5000 (Phone), (718) 918-6318 (Fax)
Certifications:
Internal Medicine, 1987, Rheumatology, 1990
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1400 Pelham Pkwy S, Bronx 10461
JACOBI MEDICAL CENTER
1400 Pelham Pkwy S, Bronx 10461
Jacobi Medical Center
1400 Pelham Pkwy South, Bronx 10461
JACOBI MEDICAL CENTER
1400 Pelham Pkwy S, Bronx 10461
Jacobi Medical Center
1400 Pelham Pkwy South, Bronx 10461
Education:
Medical School
Yale University
Graduated: 1984
Temple University Hospital
Brigham and Womens Hospital
Yale University
Graduated: 1984
Temple University Hospital
Brigham and Womens Hospital
Mycobacterial Mutants Affecting Host Apoptosis
US Patent:
8394388, Mar 12, 2013
Filed:
Jan 12, 2006
Appl. No.:
11/794506
Inventors:
Steven A. Porcelli - Bronx NY, US
Volker Briken - Burtonsville MD, US
Miriam Braunstein - Chapel Hill NC, US
Volker Briken - Burtonsville MD, US
Miriam Braunstein - Chapel Hill NC, US
Assignee:
Albert Einstein College of Medicine of Yeshiva University - Bronx NY
International Classification:
A61K 39/04, C12N 1/20
US Classification:
4242481, 4241841, 4352531
Abstract:
Provided are recombinant having a mutation in an nlaA gene or in a nuoG gene. Also provided are isolated and purified nlaA proteins and nuoG proteins from a. Additionally provided are isolated and purified nucleic acids comprising a recombinant nlaA gene or a recombinant nuoG gene. Further provided are methods of inducing an immune response in a mammal and methods of making a recombinant using the nlaA gene or the nuoG gene.
Steven Porcelli, Bronx NY
Specialties:
Internist
Address:
1400 Pelham Pkwy S, Bronx, NY 10461
Ceramide Derivatives As Modulators Of Immunity And Autoimmunity
US Patent:
7772380, Aug 10, 2010
Filed:
Aug 26, 2005
Appl. No.:
11/211653
Inventors:
Steven A. Porcelli - Bronx NY, US
Assignee:
Albert Einstein College of Medicine of Yeshiva University - Bronx NY
International Classification:
C07H 17/02
US Classification:
536 179
Abstract:
α-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are pharmaceutical compositions of the ceramide-like glycolipids combined with dendritic cells. Methods utilizing the ceramide-like glycolipids in vaccines, to activate NK T cells, to stimulate the immune system, and to treat mammals are also provided. The invention also provides methods of evaluating a compound for its ability to activate an NK T cell in the presence of a cell expressing a CD1d protein.
Ceramide Derivatives As Modulators Of Immunity And Autoimmunity
US Patent:
8022043, Sep 20, 2011
Filed:
Apr 23, 2007
Appl. No.:
11/785988
Inventors:
Steven A. Porcelli - Bronx NY, US
Assignee:
Albert Einstein College of Medicine of Yeshiva University - Bronx NY
International Classification:
A61K 31/70
US Classification:
514 25, 536 179
Abstract:
α-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are pharmaceutical compositions of the ceramide-like glycolipids combined with dendritic cells. Methods utilizing the ceramide-like glycolipids in vaccines, to activate NK T cells, to stimulate the immune system, and to treat mammals are also provided. The invention also provides methods of evaluating a compound for its ability to activate an NK T cell in the presence of a cell expressing a CD1d protein.
Bacterial Vaccines With Cell Wall-Associated Ceramide-Like Glycolipids And Uses Thereof
US Patent:
2010018, Jul 22, 2010
Filed:
Jan 8, 2010
Appl. No.:
12/684685
Inventors:
Steven A. Porcelli - Bronx NY, US
Manjunatha M. Venkataswamy - Bronx NY, US
Manjunatha M. Venkataswamy - Bronx NY, US
Assignee:
Albert Einstein College of Medicine of Yeshiva University - Bronx NY
International Classification:
A61K 39/02, C12N 1/20, A61K 38/21
US Classification:
424 854, 4352521, 4352531, 4352528, 4242341
Abstract:
The invention is directed compositions and methods related to bacterial cells physically associated with ceramide-like glycolipids. The invention allows for delivery of ceramide-like glycolipid adjuvants directly to the same cells that become infected with a bacterial vaccine. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.
Ceramide-Like Glycolipid-Associated Bacterial Vaccines And Uses Thereof
US Patent:
2013016, Jun 27, 2013
Filed:
Jul 6, 2011
Appl. No.:
13/808495
Inventors:
Steven A. Porcelli - Bronx NY, US
Manjunatha M. Venkataswamy - Bronx NY, US
Manjunatha M. Venkataswamy - Bronx NY, US
Assignee:
Albert Einstein College of Medicine of Yeshiva University - Bronx NY
International Classification:
A61K 39/39, A61K 39/21, A61K 39/04
US Classification:
42419711, 4352521, 4352531, 4352528, 4352523
Abstract:
The invention is directed compositions and methods related to bacterial cells that are physically associated with ceramide-like glycolipids for use as antigen carriers for heterologous antigens. The invention further relates to methods of incorporating ceramide-like glycolipid to bacterial cell walls. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.
Presentation Of Hydrophobic Antigens To T-Cells By Cd1 Molecules
US Patent:
6238676, May 29, 2001
Filed:
Jul 12, 1995
Appl. No.:
8/501600
Inventors:
Steven A. Porcelli - Bronx NY
Michael B. Brenner - Newton MA
Evan M. Beckman - Sudbury MA
Stephen T. Furlong - Wilmington DE
Michael B. Brenner - Newton MA
Evan M. Beckman - Sudbury MA
Stephen T. Furlong - Wilmington DE
Assignee:
Brigham and Women's Hospital - Boston MA
International Classification:
A61K 3904, C07K 1400
US Classification:
4242481
Abstract:
Provided are CD-1 presented antigens, compositions, cells, inhibitors and methods relating to the use of hydrophobic antigen presentation by CD1 molecules, including:
methods for detecting the presence of a CD1-presented hydrophobic antigen in a sample;
methods for isolating such CD1-presented antigens and the isolated antigens;
vaccines containing CD1-presented antigens and vaccination methods;
methods of blocking CD1 antigen presentation;
methods of identifying and/or isolating CD1 blocking agents and the isolated CD1 blocking agents;
methods of inducing CD1 expression; and
T-cells for use in the methods disclosed.
Presentation Of Hydrophobic Antigens To T-Cells By Cd1 Molecules
US Patent:
7063844, Jun 20, 2006
Filed:
May 21, 2001
Appl. No.:
09/861963
Inventors:
Steven A. Porcelli - Bronx NY, US
Michael B. Brenner - Newton MA, US
Evan M. Beckman - Sudbury MA, US
Stephen T. Furlong - Wilmington DE, US
Michael B. Brenner - Newton MA, US
Evan M. Beckman - Sudbury MA, US
Stephen T. Furlong - Wilmington DE, US
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA
International Classification:
A61K 39/40, A61K 39/42, A61K 39/395
US Classification:
4241431, 4241501, 4241511, 4241561
Abstract:
Provided are CD-1 presented antigens, compositions, cells, inhibitors and methods relating to the use of hydrophobic antigen presentation by CD1 molecules, including: methods for detecting the presence of a CD1-presented hydrophobic antigen in a sample; methods for isolating such CD1-presented antigens and isolated antigens; vaccines containing CD1-presented antigens and vaccination methods; methods of blocking CD1 antigen presentation; methods of identifying and/or isolating CD1 blocking agents and the isolated CD1 blocking agents; methods of inducing CD1 expression; and T-cells for use in the methods disclosed herein.
Mycobacterial Seca2 Mutants
US Patent:
8101191, Jan 24, 2012
Filed:
Jan 11, 2007
Appl. No.:
12/087628
Inventors:
Steven A. Porcelli - Bronx NY, US
Miriam Braunstein - Chapel Hill NC, US
Miriam Braunstein - Chapel Hill NC, US
Assignee:
Albert Einstein College of Medicine of Yeshiva University - Bronx NY
The University of North Carolina at Chapel Hill - Chapel Hill NC
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
A61K 39/04
US Classification:
4242481, 4351721, 435243
Abstract:
Provided are mycobacteria comprising (a) a mutation that is not in a SecA2 gene that attenuates the virulence of the mycobacteria in a mammalian host, and (b) a mutation in a SecA2 gene that eliminates SecA2 activity. Also provided are mycobacteria that comprise a mutation in a SecA2 gene that eliminates SecA2 activity, where the mycobacteria are not or. Additionally provided are methods of inducing an immune response in a mammal and methods of inducing an immune response to a pathogenic in a human using the above mycobacterial mutants.